Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global Preclinical CRO Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts


DUBLIN, Dec. 2, 2021 /PRNewswire/ -- The "Preclinical CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global preclinical CRO market reached a value of US$ 4.6 Billion in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 8.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

A preclinical contract research organization (CRO) is a support center that provides expertise in research and development (R&D). It ensures that a medication or therapeutic gadget is sheltered and successfully developed before being launched in the market. It offers services that assist in clearing a pharmaceutical item through animal testing and advancing it to the clinical phase. Moreover, it provides critical studies to researchers, restorative workforce, different industries and legislative contacts for assessing drug efficacy and safety in animal models and completing Investigational New Drug (IND) filing studies.

The emerging trend of outsourcing represents one of the key factors impelling the market growth. Apart from this, preclinical CROs offer end-to-end services, such as toxicology testing, which is also contributing to the market growth. Furthermore, the market has witnessed a significant change in the process of drug approval by the Food and Drug Administration (FDA). The process now subjects the drug candidate to preclinical studies for establishing its safety and effectivity among humans before the approval. Besides this, the 21st Century Cures Act was passed by the United States Congress in 2016 to accelerate medical product development and fasten the approval process for the launch of medical devices and drugs. These initiatives are positively influencing the demand for preclinical CRO services. Other major factors, including the readily available skilled human resources, low cost of devices, and the increasing prevalence of chronic diseases, are anticipated to fuel the growth of the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories Inc., Covance Inc. (Laboratory Corporation of America Holdings), Eurofins Scientific, ICON Plc, MD Biosciences Inc. (MLM Medical Labs), Medpace, Parexel International Corporation, PPD Inc. and Wuxi AppTec.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Preclinical CRO Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Service
6.1 Bioanalysis and DMPK Studies
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Toxicology Testing
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by End Use
7.1 Biopharmaceutical Companies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Government and Academic Institutes
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Medical Device Companies
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Charles River Laboratories Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Covance Inc. (Laboratory Corporation of America Holdings)
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 SWOT Analysis
13.3.3 Eurofins Scientific
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.4 ICON Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 MD Biosciences Inc. (MLM Medical Labs)
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Medpace
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Parexel International Corporation
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 SWOT Analysis
13.3.8 PPD Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Wuxi AppTec
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials

For more information about this report visit https://www.researchandmarkets.com/r/9usttr

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: